Zarrindast Mohammad-Reza, Mohajeri Sanaz
Department of Pharmacology and Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran.
Eur J Pharmacol. 2006 Dec 15;552(1-3):90-8. doi: 10.1016/j.ejphar.2006.08.091. Epub 2006 Sep 16.
In the present study, we have investigated the effect of nicotine and diazoxide, a potassium channel opener and glibenclamide, a potassium channel (K(ATP)) blocker on naloxone-precipitated physical withdrawal signs, including jumping and diarrhea. Then, the interactions of nicotine with diazoxide and glibenclamide were tested. Mice were rendered dependent on morphine by subcutaneous (s.c.) injections of morphine sulphate 3 times a day for 3 days, and jumping behavior and diarrhea were induced by intraperitoneal (i.p.) administration of naloxone 2 h after the 10th injection of morphine sulphate on day 4. Nicotine was administered 15 min and diazoxide and glibenclamide 30 min before naloxone injection. Nicotine (0.01-1 mg/kg, s.c.) and (0.1-1 mg/kg) reduced withdrawal jumping and diarrhea respectively. Diazoxide (8-64 mg/kg, i.p.) decreased jumping behavior significantly, but had no significant effect on diarrhea. On the other hand glibenclamide (0.25-1 mg/kg i.p.) and (1 mg/kg) augmented jumping and diarrhea respectively. The response of nicotine on jumping or on diarrhea was potentiated by diazoxide and decreased by glibenclamide pretreatment. The isobolographic analysis revealed synergistic interaction between diazoxide and nicotine on decreasing physical withdrawal signs including jumping and diarrhea in morphine-dependent mice. According to these results the interaction of nicotine with the K(ATP) channel opener and blocker in morphine physical withdrawal signs could be explained by direct and indirect effects of nicotine on membrane potassium currents.
在本研究中,我们研究了尼古丁、钾通道开放剂二氮嗪和钾通道(K(ATP))阻滞剂格列本脲对纳洛酮诱发的身体戒断症状(包括跳跃和腹泻)的影响。然后,测试了尼古丁与二氮嗪和格列本脲的相互作用。通过每天皮下注射硫酸吗啡3次,连续3天使小鼠对吗啡产生依赖性,并在第4天第10次注射硫酸吗啡2小时后腹腔注射纳洛酮诱发跳跃行为和腹泻。在注射纳洛酮前15分钟给予尼古丁,30分钟给予二氮嗪和格列本脲。尼古丁(0.01 - 1毫克/千克,皮下注射)和(0.1 - 1毫克/千克)分别减少了戒断性跳跃和腹泻。二氮嗪(8 - 64毫克/千克,腹腔注射)显著降低了跳跃行为,但对腹泻无显著影响。另一方面,格列本脲(0.25 - 1毫克/千克,腹腔注射)和(1毫克/千克)分别增强了跳跃和腹泻。二氮嗪预处理增强了尼古丁对跳跃或腹泻的反应,而格列本脲预处理则降低了该反应。等效线图分析显示,在降低吗啡依赖小鼠包括跳跃和腹泻在内的身体戒断症状方面,二氮嗪和尼古丁之间存在协同相互作用。根据这些结果,尼古丁在吗啡身体戒断症状中与K(ATP)通道开放剂和阻滞剂的相互作用可以通过尼古丁对膜钾电流的直接和间接作用来解释。